Overview

Glutamate Reducing Interventions in Schizophrenia

Status:
Suspended
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Participants will be administered several doses of POMA (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use MRI brain imaging to determine whether these doses of POMA are affecting glutamate levels.
Phase:
Phase 1
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborator:
National Institute of Mental Health (NIMH)